Sam Falsetti, PhD of Cambridge Biomarketing discusses the role of rare disease advocacy groups.
Sam Falsetti PhD
Sam Falsetti, PhD of Cambridge Biomarketing discusses some recent health care trends, specifically focusing on possible changes to the Affordable Care Act and drug development as it affects the rare disease community. Before private insurance market rules that were enforced in the ACA (in 2014), health insurance sold in the individual market in most states was medically underwritten. That means insurers evaluated the health status, health history, and other risk factors of applicants to determine whether and under what terms to issue coverage. To what extent people with pre-existing health conditions are protected is likely to be a central issue in the debate over repealing and replacing the ACA. It is estimated that 27% of adult Americans under the age …
Sam Falsetti, PhD of Cambridge Biomarketing discusses some of the biotech and rare disease successes of 2017, including the emergence of RNA therapies with the approval of Exondys 51 for Duchenne muscular dystrophy, as well as gene and CAR-T therapies that have had significant FDA approvals in 2017.